Taipei Exchange - Delayed Quote TWD

AP Biosciences Inc (6945.TWO)

Compare
42.25
-1.15
(-2.65%)
At close: 2:37:27 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Jeng-Horng Her Ph.D. CEO, Manager, & Director -- -- --
Vincent Huang Director of Accounting & Finance -- -- --
Tseng Winnie Director of Administration -- -- --

AP Biosciences Inc

No. 508, Zhongxiao East Road
11th Floor-2 Section 7 Nangang District
Taipei City, 115011
Taiwan
886 2 2653 2886 https://www.apbioinc.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
37

Description

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.

Corporate Governance

AP Biosciences Inc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers